Shots:
- Roche has entered into a definitive merger agreement to acquire PathAI, building on their 2021 partnership, which scaled up in 2024 to incl. the development of AI-enabled companion diagnostic algorithms
- As per the deal, Roche will acquire PathAI for $750M upfront & ~$300M in additional milestone payments; closing is expected in H2’26
- The acquisition strengthens Roche’s position in digital pathology by advancing AI-driven automation & precision medicine capabilities, while integrating PathAI’s expertise in clinical trial support & translational research
Ref: Globenewswire | Image: PathAI | Press Release
Related News: C4 Therapeutics and Roche Enter Oncology Collaboration Worth Over $1B to Develop DAC with Payload
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
